DBVT Nov 2024 2.500 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.2000 |
| Strike | 2.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 21 |
GlobeNewswireDBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.1
- GlobeNewswire
DBV Technologies Announces Results of its 2024 Combined General Meeting
Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaire
- GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conferences
Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Confer
